ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

QURE vs STOK // ALTMAN Z-SCORE & DEBT/EQUITY

uniQure N.V. (NASDAQ) VS. Stoke Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: QURE 1 — STOK 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QURE VS. STOK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC QURE STOK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -6.10% -28.90 STOK /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -10.17% 2.64% -12.81 STOK /fcf-yield <GO>
Operating Margin — -11.20% — TIE /operating-margins <GO>
Net Profit Margin — -3.70% — TIE /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE — 14.79 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 6/9 -2.00 STOK /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 42.9 52.3 -9.40 STOK /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.72B $1.70B $26.0M QURE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR QURE REV STOK REV QURE GROSS % STOK GROSS % QURE FCF STOK FCF
FY 2025 $519.0M $184.4M — — -$178.4M $44.9M
FY 2024 $516.0M $36.6M — — -$186.1M -$87.1M
FY 2023 $792.0M $8.8M — — -$145.9M -$81.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QURE // BETA —
STOK // BETA —